Immunopeptidomics in Tissue Immune Communication: Mechanisms, Clinical Relevance, and Emerging Advances

Abstract

Immunopeptidomics, the comprehensive study of peptides presented by major histocompatibility complex (MHC) molecules, has revolutionized our understanding of tissue immune communication. This field has offered invaluable insights into how antigen processing and presentation orchestrate immune surveillance, tolerance, and pathology across diverse tissue environments. This review synthesizes current knowledge on the epidemiology, mechanistic underpinnings, clinical features, diagnostic approaches, and therapeutic implications of immunopeptidomics, with a special focus on its integration into precision medicine and immunotherapy. The article further discusses recent technological advances in mass spectrometry, bioinformatics, and single-cell immunopeptidomics, and concludes with an appraisal of guideline recommendations, clinical relevance, and future prospects for research and practice.

Introduction

Tissue immune communication is fundamental to both maintaining homeostasis and orchestrating coordinated responses to pathogens, malignancies, and autoantigens. Central to this process is the presentation of antigenic peptides by MHC class I and II molecules, enabling immune cells to distinguish between self and non-self. Immunopeptidomics, the high-throughput characterization of these MHC-bound peptides, has emerged as a pivotal field bridging immunology, proteomics, and clinical medicine. The elucidation of immunopeptidomes across tissues has refined our understanding of immune surveillance, autoimmunity, and tumor immunology, providing a foundation for novel diagnostics and targeted therapeutics. As mass spectrometry and analytical pipelines have advanced, immunopeptidomics now delivers actionable insights into tissue-specific antigenicity and immunopathology, increasingly guiding clinical decision-making.

Epidemiology / Disease Burden

While immunopeptidomics itself is a research discipline rather than a disease entity, its study has illuminated the antigenic landscapes underlying major clinical burdens, including cancer, infectious diseases, autoimmune disorders, and transplant rejection. Tumors display highly heterogeneous immunopeptidomes, with neoantigen presentation influencing patient prognosis and response to immunotherapy. In autoimmune diseases such as type 1 diabetes and multiple sclerosis, aberrant presentation of self-peptides drives pathogenic T cell responses, whereas in chronic viral infections, viral antigens persistently shape the tissue peptidome and immune activation. The disease burden modulated by dysregulated tissue immune communication underscores the clinical imperative for detailed immunopeptidomic profiling in both research and translational settings.

Pathophysiology

At the core of tissue immune communication lies the process of antigen processing and presentation. Endogenous and exogenous proteins are proteolytically cleaved and loaded onto MHC molecules via tightly regulated cellular pathways. In professional antigen-presenting cells (APCs), such as dendritic cells and macrophages, the immunopeptidome is dynamically shaped by tissue microenvironment, inflammatory signals, and cellular stress. Alterations in proteasomal activity, transporter expression (TAP, ERAAP), and chaperone function can profoundly influence peptide repertoires, modulating susceptibility to infection, tolerance, or autoimmunity. Tumor cells frequently downregulate MHC expression or alter peptide presentation to evade immune detection. Immunopeptidomics elucidates these mechanisms, revealing how tissue-specific and context-dependent peptide landscapes govern immune cell recruitment, activation, or suppression.

Risk Factors

Genetic, epigenetic, and environmental factors collectively influence tissue immunopeptidomes and susceptibility to immune-mediated disease. Polymorphisms in HLA alleles dictate the peptide-binding repertoire, with certain alleles conferring risk for autoimmune conditions or differential responses to infection. Epigenetic modifications, such as DNA methylation or histone acetylation, can alter antigen processing machinery and MHC expression. Chronic inflammation, infection, and neoplastic transformation reshape the immunopeptidome by inducing stress responses and altering protein turnover. Iatrogenic factors—including immunosuppressive therapies and biologics—may further modulate peptide presentation, impacting both efficacy and adverse event profiles in clinical practice.

Clinical Features

The clinical manifestations of altered tissue immune communication are diverse, reflecting the underlying immunopeptidomic landscape. In oncology, tumors with high neoantigen load often exhibit robust immune infiltration and favorable responses to checkpoint inhibitors. Conversely, immune escape via abnormal peptide presentation correlates with treatment resistance. Autoimmune diseases frequently present with tissue-specific symptoms linked to aberrant self-peptide display, such as beta-cell destruction in type 1 diabetes or demyelination in multiple sclerosis. In transplant medicine, donor-recipient mismatches in immunopeptidomes can precipitate alloreactivity and graft rejection. Immunopeptidomics thus informs not only disease pathogenesis but also clinical presentation and progression.

Diagnosis

Diagnostic applications of immunopeptidomics are rapidly evolving. Mass spectrometry-based profiling of MHC-associated peptides from patient tissues or fluids enables the identification of disease-specific antigens, neoepitopes, and biomarkers. In oncology, immunopeptidomic signatures guide the selection of personalized cancer vaccines and predict immunotherapy responsiveness. In autoimmunity, detection of aberrant self-peptides may facilitate early diagnosis and risk stratification. Analytical advancements, including improved sample preparation, data-independent acquisition (DIA), and high-resolution bioinformatics pipelines, have enhanced sensitivity and reproducibility, supporting the integration of immunopeptidomics into clinical workflows.

Treatment & Management

Therapeutic strategies leveraging immunopeptidomic insights are transforming clinical management across multiple domains. Personalized neoantigen vaccines, adoptive T cell therapies, and bispecific antibodies are increasingly guided by patient-specific immunopeptidomes. In autoimmune diseases, interventions targeting peptide processing pathways or blocking pathogenic peptide-MHC interactions are under investigation. In transplantation, immunopeptidomic matching and monitoring may reduce alloreactivity and improve graft survival. A multidisciplinary approach integrating immunopeptidomic data with genomics, transcriptomics, and clinical parameters is essential for optimizing patient outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable advances in immunopeptidomics and its clinical translation. Single-cell immunopeptidomics now enables mapping of peptide presentation at unprecedented resolution, uncovering tissue-specific and cell-type-restricted antigen landscapes. Artificial intelligence and machine learning algorithms facilitate the prediction of peptide-MHC binding and immunogenicity, accelerating neoantigen discovery and vaccine design. Emerging therapies include off-the-shelf TCR-mimic antibodies, engineered TCRs, and inhibitors of peptide processing enzymes, many of which are currently in clinical trials. Moreover, integration of spatial proteomics with immunopeptidomics is unraveling the topographical complexity of tissue immune communication, paving the way for truly personalized immunotherapies.

Guideline Recommendations

While formal clinical guidelines for immunopeptidomics are still in development, expert consensus emphasizes standardization in sample collection, data analysis, and reporting to ensure reproducibility and clinical utility. The Human Immunopeptidome Project and allied consortia advocate for open-access databases and interoperable analytical frameworks. In oncology, the use of immunopeptidomic profiling to guide vaccine and T cell therapy selection is increasingly endorsed by expert panels. Future guidelines are expected to address quality control, clinical validation, and integration with other omics modalities, supporting broader adoption in both research and clinical practice.

Conclusion

Immunopeptidomics has emerged as a transformative discipline at the nexus of immunology, proteomics, and clinical medicine. By elucidating the molecular dialogues that underpin tissue immune communication, it offers unprecedented opportunities for disease diagnosis, risk stratification, and personalized therapy. Continued advances in analytical technologies, computational modeling, and translational research are poised to further enhance its impact, driving a new era of precision immunology and patient-centered care. As clinical guidelines evolve and integration with multi-omics platforms advances, immunopeptidomics will play an increasingly central role in shaping the future of medical practice.